Distribution characteristics of drug resistance mutations of HIV CRF01_AE, CRF07_BC and CRF08_BC from patients under ART in Ganzhou, China.
PMID: 34402512
2021
The Journal of antimicrobial chemotherapy
Abstract: The most common DRMs of these three subtypes were K103N and M184V, while the mutation frequencies of M41L, D67N, K70R, K101E, V106M, Y181C, K219E, H221Y and N348I were obviously different among subtypes.
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
PMID: 34397746
2021
Journal of acquired immune deficiency syndromes (1999)
Result:
Result: Altogether, 68 participants with baseline NRTI resistance (including 50 with M184V/I) received B/F/TAF during the study and had postswitch virologic data.
Result: Among participants with M184V or I mutations at baseline 97% (30 of 31) on B/F/TAF and 95% (19 of 20) on SBR had HIV-1 RNA <50 copies/mL at week 24.
Result: At baseline, 13% (44 of 328) in the B/F/TAF group and 16% (26 of 165) in the SBR group had NRTI resistance, including 9% (31 of 328) and 12% (20 of 165) with M184V/I mutations in the B/F/TAF and SBR groups, respectively.
Result: One participant with M184V on B/F/TAF discontinued after the baseline visit and did not have virologic data at week 24.
Table: M184V/I
HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.
Abstract: The most common DRMs were M184I/V (42.2%), followed by V179D/E (37.9%) and K65R (27.2%).
Discussion: M184I/V (42.2%) was the most prevalent NRTI-associated mutation, which might be caused
Discussion: A high frequency of K65R plus M184V/I (15.0%) was observed in this study, and K65R plus M184 V/I appeared sufficient to abrogate the NRTI activity of a regimen comprising ABC, TDF or D4T.
Discussion: In contrast, M184I/V increased susceptibility to Zidovudine (AZT), Stavudine (D4T) and TDF and slowed the emergence of AZT, D4T, and TDF resistance.
Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
Abstract: M184V/I mutations in the reverse transcriptase gene were newly detected in three people with VF.
Evaluation of minor drug-resistant viral variants in patients experiencing virological failure (VF) on a first-line regimen in Fujian Province by high-throughput sequencing.
Abstract: RESULTS: NRTI drug resistant mutations (DRMs) were detected in a high proportion of subjects, with the most common being M184V and TAMs.
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.
PMID: 34327247
2021
Open forum infectious diseases
Abstract: In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least
Discussion: However, previous observational studies suggested an increased risk of VF during 3TC-based DT when M184V/I was present in combination with a shorter time of viral suppression.
Discussion: Indeed, M184V/I and TAMs appear to synergize with each other since TAMs alone were not associated with VF.
Discussion: Our study showed that a shorter duration of virological suppression and the presence of M184V/I were independent predictors of VF; however, M184V/I alone was less accurate in predicting the outcome than its combination with TAMs.
Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.
Abstract: The TDF/FTC DRMs included K65R (8/13), M184I/V (5/13), and Y115F (2/13).
Introduction: The main drug resistance mutations (DRMs) to TDF/FTC include K65R and M184I/V, but the global
Result: K65R is known to confer high-level resistance to TDF and intermediate-level resistance to FTC, while M184I/V confers high-level resistance to FTC and 3TC and low-level resistance to abacavir (ABC).
Result: The mutations included K65R (61.5%, 8/13), M184I/V (38.5%, 5/13), and Y115F (2/13).
Table: M184M/V
Table: M184V
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Abstract: CONCLUSIONS: In this real-world cohort, the majority of whom had virus with the M184V/I and >= 1 additional NA mutation, switching to DTG functional mono-or dual therapy with a non-cytosine NA resulted in persistent HIV-1 RNA >= 50 copies/mL in 18%.
Abstract: Historical genotypes indicated that all had an M184V/I, and 23 (59%) had an M184V/I and >= 1 additional NA mutation.
Introduction: In both the GEMINI and TANGO studies, patients with baseline nucleoside reverse transcriptase inhibitor (NRTI) resistance include those with M184V/I and integrase strand transfer inhibitor (INSTI) resistance were excluded.
Introduction: Prior reports have demonstrated a h
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
Result: Five SDRMs increased in prevalence among NRTI-experienced persons including K65R, K70E, Y115F, and M184V/I.
High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.
Abstract: Of the 27 viraemic isolates successfully genotyped, 20 (74.1%) carried DR mutations; most frequent were M184VI (55.6%), K103N (37.1%), thymidine analog mutations (29.6%), Y181CY (22.2%).
Result: FTC and 3TC were also predicted with high-level DR (55.6%), which however is associated with a higher fitness cost due to the point mutation M184V.
Result: For NRTIs, these were M184VI (55.6%), T215SNY (22.2%), and K65R (18.5%).
Table: M184V
Discussion: In subgroup analysis of DR, most widespread DRMs among failing patients were 3TC-resistance M184V and NVP-resistance
HIV mutation literature information.
PMID: 
2021
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT